ASULACRINE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H24N4O4S
Molecular Weight	464.537
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CNC(=O)C1=CC=CC2=C1N=C3C(C)=CC=CC3=C2NC4=C(OC)C=C(NS(C)(=O)=O)C=C4

InChI

InChIKey=TWHSQQYCDVSBRK-UHFFFAOYSA-N

InChI=1S/C24H24N4O4S/c1-14-7-5-8-16-21(14)27-23-17(9-6-10-18(23)24(29)25-2)22(16)26-19-12-11-15(13-20(19)32-3)28-33(4,30)31/h5-13,28H,1-4H3,(H,25,29)(H,26,27)

HIDE SMILES / InChI

Description

Asulacrine, also known as CI-921, an inhibitor of topoisomerase II, participated in clinical trials phase II for the treatment of cancer. In spite of the positive and promising results, this drug showed the toxicity, phlebitis that blocks its implementation in the future.

Originator

Approval Year

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Intravenous

Show entries

Name

Type

Language

ASULACRINE

Common Name

English

AMSALOG

Brand Name

English

SN-21407

Code

English

4-ACRIDINECARBOXAMIDE, 9-((2-METHOXY-4-((METHYLSULFONYL)AMINO)PHENYL)AMINO)-N,5-DIMETHYL-

Systematic Name

English

CI-921

Code

English

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Antineoplastic Agent

NCI_THESAURUS

C1968

DNA Binding Agent

NCI_THESAURUS

C582

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Code System

Code

Type

Description

FDA UNII

S8P50T62B6

PRIMARY

CAS

80841-47-0

PRIMARY

PUBCHEM

107924

PRIMARY

NCI_THESAURUS

C91758

PRIMARY

DRUG CENTRAL

252

PRIMARY

Showing 1 to 5 of 8 entries

Previous1 2Next

ACTIVE MOIETY


					S8P50T62B6

ASULACRINE

SALT/SOLVATE (PARENT)


					649R3P169I

ASULACRINE ISETHIONATE